Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) just unveiled an update.
Paradigm Biopharmaceuticals Ltd announced the completion of issuing 8,000,000 fully paid ordinary shares as part of a Convertible Securities Agreement. This move aligns with the company’s compliance with relevant provisions of the Corporations Act, ensuring transparency and adherence to regulatory standards, which may bolster stakeholder confidence and support the company’s strategic financial initiatives.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd is a company operating in the biopharmaceutical industry, focusing on the development and commercialization of therapies for unmet medical needs.
Average Trading Volume: 854,010
Technical Sentiment Signal: Sell
Current Market Cap: A$124.6M
See more data about PAR stock on TipRanks’ Stock Analysis page.